Revvity says it will exceed 2025 profit forecast range
Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models
Revvity teams up with Eli Lilly to bring TuneLab AI models to Signals Xynthetica, aiming to unlock secure, federated drug discovery at scale.
Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica
RVTY unveils Signals Xynthetica, an AI-augmented design platform that links predictive models with real lab data to speed discovery.
Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
Revvity, Inc. (RVTY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Revvity, Inc. ( RVTY ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Prahlad Singh - CEO, President & Director Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay. Thank you.
RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised
Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.
Revvity (RVTY) Surpasses Q3 Earnings Estimates
Revvity (RVTY) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.28 per share a year ago.
Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?
RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.
RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes
Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection, expanding its reach beyond rare diseases.
Revvity Q2: Headwinds From China And Customers, Buy On Weakness
Revvity, Inc.'s focus on high-growth markets like cell and gene therapies and precision medicine positions it for long-term expansion despite near-term challenges. The recent divestiture streamlines Revvity's portfolio, allowing greater investment in specialized diagnostics and software, which are expected to drive future growth. While facing weak academic/government demand and China headwinds, Revvity maintains a strong capital structure and margin expansion potential through cost optimization.
Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook
Revvity (RVTY) was one of the worst-performing stocks in the S&P 500 Monday after the medical device maker said it anticipated a "meaningful pullback" in its immunodiagnostics business in China.
